secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001493152-22-030288
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Phase 3 VIITAL study of EB-101 meets co-primary endpoints; BLA submission planned Q2 2023
--------------------------------------------------------------------------------

- 81.4% of treated wounds achieved ≥50% healing vs 16.3% controls (p<0.0001).
- Pain reduction co-primary endpoint met: mean reduction 3.07 treated vs 0.90 control (p=0.0002).
- No serious treatment-related adverse events; consistent with past safety profile.
- BLA submission to FDA for EB-101 in RDEB targeted for Q2 2023.
- EB-101 has Orphan Drug and Rare Pediatric Disease designations, may qualify for Priority Review Voucher.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315222030288/0001493152-22-030288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315222030288/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer